Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform. (April 2021)

• Record Type: Journal Article
• Authors: Wang, Zi-Xian; Yao, Yi-Chen; Mai, Zong-Jiong; Lin, Wu-Hao; Huang, You-Sheng; Jin, Ying; Luo, Hui-Yan; Zhang, Dong-Sheng; Wang, Feng-Hua; Wang, Feng; Chen, Gong; Ding, Pei-Rong; Yuan, Yun-Fei; Li, Yu-Hong; Huang, Jin-Hua; Pan, Zhi-Zhong; Xu, Rui-Hua
• Is Part Of: Engineering. Volume 7:Number 4(2021)
• Page Start: 526
• Page End: 533
• Publication Date: 2021-04
• Subjects: Metastatic colorectal cancer -- Real-world evidence -- Treatment pattern -- Survival -- Big-data platform; Engineering -- Periodicals; Engineering -- China -- Periodicals; 620.005
• DOI: 10.1016/j.eng.2020.10.017
• Languages: English
• ISSNs: 2095-8099

Abstract

Abstract: There is a lack of high-quality, large-scale, real-world evidence from patients with metastatic colorectal cancer (mCRC), especially in China. It remains unclear whether efforts to improve the quality of care for mCRC would improve patient survival outcomes in real-world practice. On the basis of an intelligent big-data platform, we established a large-scale retrospective cohort of mCRC patients. We investigated the temporal changes in the systemic and local treatment (resection, ablation, or radiation to liver, lung, or extrahepatic and/or extrapulmonary metastases) patterns of mCRC, and whether these changes were associated with improved overall survival (OS) over time. Between July 2012 and December 2018, 3403 eligible patients were included in this research. The median OS was 42.8 months (95% confidence interval (CI), 40.7–46.6) for the entire cohort, 25.6 months (95% CI, 24.7–26.9) for those treated with systemic therapy only, and not reached (95% CI, 78.6 months–not reached) for those receiving local therapy. The utility rate of local therapy increased continuously from 37.9% in 2012–2014 to 46.9% in 2017–2018. A dramatic increase in the utility rate of either cetuximab or bevacizumab was observed since 2017 (39.9%, 43.2%, and 60.3% in 2012–2014, 2015–2016, and 2017–2018, respectively). Compared with 2012–2014, the OS of the entire population significantly improved in 2015–2016 (hazard ratio (HR) = 0.87 (95% CI, 0.78–0.99); P = 0.034), but not for patients receiving systemic therapy only (HR = 0.99 (95% CI, 0.86–1.14); P = 0.889), whereas an improved OS was found in 2015–2018 for both the entire population (HR = 0.75 (95% CI, 0.70–0.81); P < 0.001) and for patients receiving systemic therapy only (HR = 0.83 (95% CI, 0.77–0.91); P < 0.001). In summary, the quality of care for mCRC, as indicated by the utility rate of targeted and local therapies, has been continuously improving over time in this study cohort, which is associated with continuously improving survival outcomes for these patients.